{'fraction_non_alphanumeric': 0.016835016835016835, 'fraction_numerical': 0.0, 'mean_word_length': 5.656716417910448, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Mechanism and treatment of cancer metastasis to bone].

Bone is one of the most preferential metastatic target sites for cancers such as breast, prostate and lung cancers. Although the precise molecular mechanisms underlying this predilection are still unclear, it appears that these cancer cells possess the capacity to modulate bone microenvironments for them to arrest, survive and proliferate. In particular, the production of bone-resorbing cytokines by these cancer cells increases osteoclastic bone resorption, which in turn facilitates the colonization of these cancer cells in bone through abundant supplies of bone-stored growth factors. This crosstalk between metastatic cancer cells and bone promotes the development and progression of bone metastases. Disruption of this vicious cycle using bisphosphonates will allow us to effectively and specifically inhibit bone metastases.